Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Anti-Adalimumab Antibodies in Children With Juvenile Idiopathic Arthritis and/or Chronic Non-Infectious Uveitis (ADA AIG-U)

12 november 2026 bijgewerkt door: Gabriele Simonini, Meyer Children's Hospital IRCCS

Anti-Adalimumab Antibodies in a Prospective Cohort of Patients With Juvenile Idiopathic Arthritis and/or Chronic Non-Infectious Uveitis: Incidence, Predictive Factors, and Clinical Correlations

This prospective, single-center observational cohort study aims to investigate the development of anti-Adalimumab antibodies in pediatric patients with juvenile idiopathic arthritis (JIA) and/or chronic non-infectious uveitis initiating Adalimumab treatment.

The study will assess the frequency and timing of antibody development, identify potential predictive factors, including concomitant methotrexate treatment, and explore associations between immunogenicity, serum Adalimumab concentrations, disease activity, and clinical outcomes.

A total of 60 patients will be enrolled and followed for 24 months. Clinical data and additional blood samples will be collected at baseline and at 3, 6, 12, 18, and 24 months during routine clinical visits.

Anti-Adalimumab antibodies and serum drug concentrations will be measured using surface plasmon resonance (SPR) technology. Treatment decisions will remain entirely based on routine clinical practice.

Studie Overzicht

Toestand

Werving

Interventie / Behandeling

Gedetailleerde beschrijving

Adalimumab is widely used in the treatment of juvenile idiopathic arthritis (JIA) and chronic non-infectious uveitis. Despite its established efficacy, some patients experience inadequate clinical response, secondary loss of efficacy, or disease flares during treatment. The development of anti-Adalimumab antibodies (AAA) may contribute to reduced serum drug concentrations and impaired therapeutic response. However, evidence regarding the incidence, timing, and clinical significance of AAA in paediatric patients remains limited and heterogeneous.

This prospective, single-centre, observational cohort study aims to investigate the development and kinetics of AAA in paediatric patients with JIA and/or chronic non-infectious uveitis initiating Adalimumab treatment. The study will also explore potential predictive factors for AAA development, including concomitant methotrexate therapy, and evaluate associations between immunogenicity, serum Adalimumab concentrations, disease activity, and clinical outcomes.

A total of 60 Adalimumab-naïve patients will be consecutively enrolled at AOU Meyer IRCCS, Florence, Italy. All participants will receive Adalimumab according to routine clinical practice, independently of study participation. No investigational treatment or study-related therapeutic intervention is planned.

Each participant will be followed for 24 months, with assessments at baseline and at 3, 6, 12, 18, and 24 months. Clinical and laboratory data will be collected during routine follow-up visits, including demographic characteristics, disease subtype and duration, concomitant treatments, disease activity measures, inflammatory markers, disease flares, and treatment modifications.

At each scheduled assessment, an additional 5 mL peripheral blood sample will be collected during routine blood sampling. Serum samples will be analysed at the PeptLab laboratory of the University of Florence using surface plasmon resonance (SPR) technology to determine AAA positivity and levels, as well as serum Adalimumab concentrations. AAA positivity will be defined according to a predefined threshold of 15 Response Units (RU).

The primary outcomes are the proportion of patients developing AAA during follow-up and the time from Adalimumab initiation to the first detection of AAA. Secondary outcomes include the identification of clinical and treatment-related factors associated with AAA development, changes in disease activity and functional assessment scores (JADAS-10 and CHAQ), inflammatory markers, occurrence and number of disease flares, and persistence of AAA positivity.

Statistical analyses will include descriptive and exploratory multivariable methods, longitudinal models for repeated measurements, and time-to-event analyses accounting for interval censoring when appropriate. Particular attention will be given to the potential association between concomitant methotrexate treatment and AAA development.

The overall study duration is expected to be 72 months, including 36 months of recruitment, individual follow-up, and final data analysis and reporting.

The study aims to improve understanding of Adalimumab immunogenicity in paediatric JIA and chronic non-infectious uveitis and to explore the potential clinical value of immunopharmacological monitoring in identifying patients at risk of secondary treatment failure or disease relapse.

Studietype

Observationeel

Inschrijving (Geschat)

60

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

2 jaar tot 17 jaar (Kind)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

Pediatric patients with juvenile idiopathic arthritis (JIA) and/or chronic non-infectious uveitis followed at the Pediatric Rheumatology Unit of AOU Meyer IRCCS, Florence, Italy, for whom initiation of Adalimumab treatment is clinically indicated.

Eligible patients must be Adalimumab-naïve and will be consecutively enrolled during routine outpatient or day-hospital visits. Treatment decisions will be made independently of study participation, according to standard clinical practice.

Beschrijving

Inclusion Criteria:

Age at diagnosis between 2 and 16 years.

Diagnosis of juvenile idiopathic arthritis (JIA) according to the International League of Associations for Rheumatology (ILAR) criteria, established on or after January 1, 2015, and/or diagnosis of chronic non-infectious uveitis according to the Standardization of Uveitis Nomenclature (SUN) Working Group criteria, established on or after January 1, 2015.

Clinical indication to initiate Adalimumab treatment in patients with no previous exposure to Adalimumab (Adalimumab-naïve), as determined by the treating physician.

Written informed consent from parents or legal guardians and assent from minors aged 7 years or older, where applicable.

Exclusion Criteria:

Age 18 years or older at enrollment.

Diagnoses other than juvenile idiopathic arthritis or chronic non-infectious uveitis.

Contraindications to Adalimumab, including tuberculosis exposure, history of multiple sclerosis or other demyelinating central nervous system disorders, or history of malignancy.

Previous exposure to Adalimumab before study enrollment.

Body weight below 12 kg.

Age below 24 months at enrollment.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Observatiemodellen: COHORT
  • Tijdsperspectieven: PROSPECTIVE

Cohorten en interventies

Groep / Cohort
Interventie / Behandeling
Adalimumab-treated patients with JIA and/or chronic non-infectious uveitis

Pediatric patients diagnosed with juvenile idiopathic arthritis (JIA) and/or chronic non-infectious uveitis who are initiating Adalimumab treatment according to routine clinical practice and have not previously received Adalimumab.

Patients will be prospectively followed for 24 months, with clinical assessments and blood sample collection at baseline and at 3, 6, 12, 18, and 24 months to evaluate the development of anti-Adalimumab antibodies, serum drug concentrations, and clinical outcomes.

Anti-Adalimumab Antibody and Serum Drug Level Assessment by SPR

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Proportion of Patients Developing Anti-Adalimumab Antibodies
Tijdsspanne: Baseline and Months 3, 6, 12, 18, and 24

Proportion of patients with detectable anti-Adalimumab antibodies (AAA) during the 24-month follow-up, assessed using surface plasmon resonance (SPR). Antibody positivity will be defined using a predefined cut-off of 15 Response Units (RU).

Baseline and Months 3, 6, 12, 18, and 24
Time to Development of Anti-Adalimumab Antibodies
Tijdsspanne: From baseline to Month 24.

Time from initiation of Adalimumab treatment to the first detection of anti-Adalimumab antibodies, assessed at scheduled follow-up visits. The analysis will account for interval censoring between the last negative and first positive antibody determinations.

From baseline to Month 24.

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Factors Associated With Anti-Adalimumab Antibody Development
Tijdsspanne: Baseline to Month 24

Assessment of the association between anti-Adalimumab antibody (AAA) development and demographic, clinical, and laboratory factors, including sex, age, JIA subtype according to ILAR classification, disease duration, baseline inflammatory markers, and serum Adalimumab concentrations.

Baseline to Month 24
Association Between Concomitant Methotrexate Treatment and AAA Development
Tijdsspanne: Baseline to Month 24

Assessment of the proportion of patients developing anti-Adalimumab antibodies according to concomitant methotrexate treatment (yes/no), including the time to antibody development where appropriate.

Baseline to Month 24
Change in Juvenile Arthritis Disease Activity Score (JADAS-10)
Tijdsspanne: Baseline and Months 3, 6, 12, 18, and 24

Assessment of changes in disease activity using the Juvenile Arthritis Disease Activity Score (JADAS-10) during follow-up and their association with anti-Adalimumab antibody development.

Baseline and Months 3, 6, 12, 18, and 24
Change in Childhood Health Assessment Questionnaire (CHAQ) Score
Tijdsspanne: Baseline and Months 3, 6, 12, 18, and 24

Assessment of changes in functional disability using the Childhood Health Assessment Questionnaire (CHAQ) during follow-up and their association with anti-Adalimumab antibody development.

Baseline and Months 3, 6, 12, 18, and 24
Change in Inflammatory Markers (ESR and CRP)
Tijdsspanne: Baseline and Months 3, 6, 12, 18, and 24

Assessment of changes in erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels during follow-up and their association with anti-Adalimumab antibody development.

Baseline and Months 3, 6, 12, 18, and 24
Proportion of Patients Experiencing at Least One Disease Flare
Tijdsspanne: Baseline to Month 24

Proportion of patients experiencing at least one articular or ocular disease flare during the 24-month follow-up, according to the definitions established in the study protocol.

Baseline to Month 24
Number of Disease Flares per Patient
Tijdsspanne: Baseline to Month 24

Total number of articular and/or ocular disease flares recorded for each patient during the 24-month follow-up period.

Baseline to Month 24
Persistence of Anti-Adalimumab Antibody Positivity
Tijdsspanne: Baseline to Month 24

Proportion of anti-Adalimumab antibody-positive patients showing persistent antibody positivity, defined as two positive determinations performed at least six months apart.

Baseline to Month 24

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

7 oktober 2026

Primaire voltooiing (Geschat)

1 oktober 2031

Studie voltooiing (Geschat)

1 oktober 2032

Studieregistratiedata

Eerst ingediend

12 november 2026

Eerst ingediend dat voldeed aan de QC-criteria

12 november 2026

Eerst geplaatst (Werkelijk)

19 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

19 november 2026

Laatste update ingediend die voldeed aan QC-criteria

12 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren